<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005534.pub2" GROUP_ID="AIRWAYS" ID="818305072222061922" MERGED_FROM="" MODIFIED="2008-09-22 12:10:55 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Editing by CJC March 1st 2006&lt;/p&gt;&lt;p&gt;Authors' Contribution: ok&lt;/p&gt;&lt;p&gt;Objectives: fine&lt;/p&gt;&lt;p&gt;References: fine&lt;/p&gt;&lt;p&gt;Table of included studies - none&lt;/p&gt;&lt;p&gt;Metaview Labels -none&lt;/p&gt;&lt;p&gt;Synopsis - fine&lt;/p&gt;&lt;p&gt;Abstract - fine&lt;/p&gt;&lt;p&gt;Background - fine. Is there any RCT evidence relating to oxygen flow after admission?&lt;/p&gt;&lt;p&gt;Methods - fine but tenses changed as the methods were not actually used.&lt;/p&gt;&lt;p&gt;Results -fine&lt;/p&gt;&lt;p&gt;Discussion - How do the 2 trials in progress alter your conclusion re the urgent need for more research. We need to know what the ongoing trials find next as far as I can see,&lt;/p&gt;&lt;p&gt;Next action - Toby please return to RWB to re above. Chris.&lt;/p&gt;&lt;p&gt;&lt;br&gt;+++++++++++++++++++++++++++++++++++++++++++++++++++++&lt;br&gt;Editing by CJC 11 August 2004&lt;/p&gt;&lt;p&gt;Authors' Contribution: brief!&lt;/p&gt;&lt;p&gt;Objectives: I assume that you are not including interventions in casualty but it might be worth explicitly mentioning this. The interventions are not clear. Do you mean high or low flow versus each other or placebo (what about usual care with no placebo given?). From the background I think your main question is whether hi flow is more effective/safe than low flow?&lt;br&gt;Is the abbreviation FiO2 or FLO2 - I have not come across this before.&lt;/p&gt;&lt;p&gt;References : checked by Liz&lt;/p&gt;&lt;p&gt;Methods: fine. I have corrected a few past tenses and amended the sentences relating to publication bias and sensitivity analysis.&lt;/p&gt;&lt;p&gt;&lt;br&gt;Next action: Please clarify the objectives as above.&lt;/p&gt;&lt;p&gt;Thanks,&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Old title: Oxygen therapy in the pre-hospital setting for people suffering from an AECOPD&lt;/p&gt;&lt;p&gt;Have amended SS section 9/8/05 Liz&lt;br&gt;Old title: #Oxygen therapy in the pre-hospital setting for people suffering from an acute exacerbation of chronic obstructive pulmonary disease&lt;br&gt;Old title: #Oxygen therapy in the pre-hospital setting for people suffering from an acute exacerbation of chronic obstructive pulmonary disease (WITH CHRIS 100805)&lt;/p&gt;" NOTES_MODIFIED="2008-09-19 16:13:05 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="OXY-COP" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.3">
<COVER_SHEET MODIFIED="2008-09-22 12:10:55 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease</TITLE>
<CONTACT MODIFIED="2008-09-22 12:10:55 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="E76A314382E26AA201E74FE9397B807A" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>A.</MIDDLE_INITIALS><LAST_NAME>Austin</LAST_NAME><EMAIL_1>maaustin@postoffice.utas.edu.au</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>1/18 Lindeith Court</ADDRESS_1><CITY>Sandy Bay</CITY><ZIP>7005</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>03 6225 1535</PHONE_1><PHONE_2>0404667762</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-09-22 12:10:55 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="E76A314382E26AA201E74FE9397B807A" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>A.</MIDDLE_INITIALS><LAST_NAME>Austin</LAST_NAME><EMAIL_1>maaustin@postoffice.utas.edu.au</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>1/18 Lindeith Court</ADDRESS_1><CITY>Sandy Bay</CITY><ZIP>7005</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>03 6225 1535</PHONE_1><PHONE_2>0404667762</PHONE_2></ADDRESS></PERSON><PERSON ID="12536" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><LAST_NAME>Wood-Baker</LAST_NAME><POSITION>Honorary Fellow</POSITION><EMAIL_1>Richard.WoodBaker@utas.edu.au</EMAIL_1><MOBILE_PHONE>0438213113</MOBILE_PHONE><ADDRESS><DEPARTMENT>Menzies Research Institute</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><ADDRESS_1>Department of Respiratory Medicine</ADDRESS_1><ADDRESS_2>GPO Box 1061</ADDRESS_2><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 3 6222 7353</PHONE_1><FAX_1>61 3 6222 7579</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-18 13:52:36 +0100" MODIFIED_BY="Toby J Lasserson">
<UP_TO_DATE>
<DATE DAY="4" MONTH="4" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="4" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-18 12:04:43 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-18 12:04:43 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="18" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Literature search re-run; no new studies found </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="15" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="4" MONTH="4" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Airways Group (Tasmania)</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-19 16:11:25 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease</TITLE>
<SUMMARY_BODY>
<P>People with Chronic obstructive pulmonary disease (COPD) are prone to sudden episodes where their symptoms become worse and oxygen levels may fall. Initial treatment during these episodes usually includes oxygen, but this may cause a rise in the carbon dioxide levels that can be dangerous. This review could not find any evidence to indicate the safest way to provide oxygen treatment in this circumstance.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-09-19 16:07:24 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality in the developed world, is characterised by acute deterioration in symptoms. During these exacerbations, people are prone to developing alveolar hypoventilation, which may be contributed to by the administration of high inspired oxygen concentrations. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of the review was to determine the effect of different inspired oxygen concentrations ("high flow" compared to "controlled") in the pre-hospital setting on outcome for people with acute exacerbations of COPD. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-09-19 16:07:24 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Airways Group Specialised Register (CENTRAL), MEDLINE, EMBASE and CINAHL and reference lists of articles. We also contacted authors of identified RCTs for details of other relevant, published and unpublished studies. The most recent search was conducted in August 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials comparing oxygen therapy at different concentrations or oxygen therapy versus placebo in the pre-hospital setting for treatment of acute exacerbations of COPD were eligible.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently assessed trial quality and extracted data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>The search identified a total of 741 abstracts, of which 18 were selected as potentially relevant, only two of the 18 studies were randomised controlled trials and eligible for inclusion in the review, but were ongoing and had no data available for analysis. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>No relevant trials have been published to date, so there is no evidence to indicate whether different oxygen therapies in the pre-hospital setting have an effect on outcome for people with acute exacerbations of COPD. There is an urgent need for robust, well-designed randomised controlled trials to investigate the effect of oxygen therapies in the pre-hospital setting for people with acute exacerbations of COPD. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-19 16:11:25 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the developed world, and is a common worldwide cause of death amongst those over the age of 45 years (<LINK REF="REF-Murray-1997" TYPE="REFERENCE">Murray 1997</LINK>; <LINK REF="REF-Gulsvik-2001" TYPE="REFERENCE">Gulsvik 2001</LINK>). The disease is characterised by acute deteriorations in the patient's condition, termed exacerbations, which are often associated with the development of respiratory failure (<LINK REF="REF-Warren-1980" TYPE="REFERENCE">Warren 1980</LINK>; <LINK REF="REF-Plant-2001" TYPE="REFERENCE">Plant 2001</LINK>). </P>
<P>COPD patients may develop alveolar hypoventilation, which results in an elevation of the partial pressure of arterial carbon dioxide (PaCO<SUB>2</SUB>), known as hypercarbia, and a reduction in partial pressure of arterial oxygen (PaO<SUB>2</SUB>), known as hypoxaemia. The combination of a PaO<SUB>2</SUB> below 60 and PaCO<SUB>2 </SUB>above 45 is referred to as hypoventilatory (hypercapnic) respiratory failure. It is associated with a poor outcome in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) (<LINK REF="REF-Groenewegen-2003" TYPE="REFERENCE">Groenewegen 2003</LINK>). Impairment of gas exchange and the development of respiratory failure may be precipitated by a variety of factors, one of which is the administration of oxygen at high concentrations. In this group of patients, the administration of high inspired concentrations of oxygen may cause a worsening of respiratory function, leading to further elevation of arterial carbon dioxide concentration. </P>
<P>Supplemental oxygen therapy in the emergency situation has traditionally been administered using "high-flow" oxygen. This approach has been adopted on the basis that the population as a whole are at greater risk from failure to correct oxygenation than from its excessive administration. Indeed, for people with AECOPD, oxygen driven nebulizers via mask at flows of 6 to 8 L/min will often be used to achieve nebulization of bronchodilator. A recent retrospective study has found that the administration of an inspired oxygen concentration above 28% was associated with a 14% in-hospital mortality, compared to a 2% in-hospital mortality for those administered a concentration of oxygen less that 28% (<LINK REF="REF-Denniston-2002" TYPE="REFERENCE">Denniston 2002</LINK>). This has raised questions about the optimal delivery of oxygen to people with COPD in the pre-hospital setting. </P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of the study is to determine the effect of different oxygen therapies in the pre-hospital setting (prior to casualty/emergency department) of acute exacerbations of COPD. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-19 16:11:25 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-09-18 12:07:02 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>Studies should be randomised controlled trials comparing oxygen therapy at different concentrations or oxygen therapy versus placebo in the pre-hospital setting for treatment of acute exacerbations of COPD. Other treatment interventions e.g. bronchodilators, corticosteroids should be standardised as far a possible for both intervention arms. Studies of acute asthma will be excluded. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants should be adults with an acute exacerbation of chronic obstructive pulmonary disease requiring medical or paramedical assistance in the pre-hospital setting. The definition of an acute exacerbation will be any combination of an increase in breathlessness, sputum volume, sputum purulence, cough or wheeze. Participants will have spirometric evidence of airflow obstruction (forced expired volume in one second (FEV<SUB>1</SUB>)/Forced Vital Capacity (FVC) &lt; 0.7) plus a smoking history of greater than 10 pack history years or be defined by an accepted standard definition e.g. GOLD, ATS. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-09-18 12:07:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Interventions include high fractional inspired concentration (FIO<SUB>2</SUB>) (&gt; 28%) oxygen therapy VERSUS placebo or low fractional inspired concentration (FIO<SUB>2</SUB>) (&lt; 28%) oxygen therapy. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-15 12:00:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-08-15 12:00:04 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Mortality from respiratory causes</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-08-15 12:00:16 +0100" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>All causes mortality</LI>
<LI>Dyspnoea score</LI>
<LI>Atrial blood gas measurements (ABG)</LI>
<LI>Duration of hospitalisation</LI>
<LI>Admission to ICU</LI>
<LI>Mental status score</LI>
<LI>Consciousness score (for example GCS)</LI>
<LI>Invasive ventilation</LI>
<LI>Non invasive ventilation</LI>
<LI>Lung function</LI>
<LI>Illness score (for example. APACHE</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-19 16:11:25 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Electronic searches</HEADING>
<P>We searched the Cochrane Airways Group Specialised Register (August 2008), CENTRAL (<I>The Cochrane Library </I>Issue 3, 2008); MEDLINE (1966 to August wk 1, 2008); EMBASE (1980 to wk 32, 2008); and CINAHL (1982 to August wk 1, 2008).</P>
<P>The following search was used in CENTRAL and adapted for MEDLINE, EMBASE and CINAHL (<I>see </I>
<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for full strategies):</P>
<P>#1. PULMONARY DISEASE CHRONIC OBSTRUCTIVE explode tree 1 (MeSH)<BR/>#2. (lung* or respirat* or pulmonar* or airway* or airflow*)<BR/>#3. BRONCHITIS CHRONIC explode tree 3 (MeSH)<BR/>#4. PULMONARY EMPHYSEMA explode tree 1 (MeSH)<BR/>#5. (chronic* near obstruct*)<BR/>#6. (#2 and #5)<BR/>#7. bronchiti*<BR/>#8. emphysema*<BR/>#9. (copd or coad or cobd)<BR/>#10. (#1 or #3 or #4 or #6 or #7 or #8 or #9)<BR/>#11. EMERGENCY MEDICAL SERVICES explode tree 1 (MeSH)<BR/>#12. emergenc*<BR/>#13. emergicent*<BR/>#14. emergi-cent*<BR/>#15. prehospital*<BR/>#16. pre-hospital*<BR/>#18. ambulance*<BR/>#19. (patient* near transport*)<BR/>#20. EMERGENCY TREATMENT explode tree 1 (MeSH)<BR/>#21. first-aid*<BR/>#22. (first next aid*)<BR/>#23. (#11 or #12 or #13 or #14 or #15 or #16 or #18 or #19 or #20 or #21 or #22)<BR/>#24. OXYGEN INHALATION THERAPY explode tree 1 (MeSH)<BR/>#25. RESPIRATORY THERAPY explode tree 1 (MeSH)<BR/>#26. OXYGEN single term (MeSH)<BR/>#27. oxygen*<BR/>#28. (inhal* near therap*)<BR/>#29. (respirat* near therap*)<BR/>#30. (nasal next cannula)<BR/>#31. (nasal next prong*)<BR/>#32. nrm<BR/>#33. hudson*<BR/>#34. venture*<BR/>#35. mask*<BR/>#36. (#24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35)<BR/>#37. (#10 and #23 and #36)</P>
<P>We searched all records in the Airways Group Register coded as 'COPD' with the terms:<BR/>(emergenc* or emergicent* or emergi-cent* or prehospital* or pre-hospital* or hospital* or ambulance* or (patient* and transport*) or first-aid* or "first aid*") AND (oxygen* or ((inhal* or respiratory*) and therap*) or "nasal cannula*" or "nasal prong*" or NRM or venture* or Hudson* or mask*)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Searching other sources</HEADING>
<P>We handsearched reference lists from studies selected by electronic searching to identify other related articles. In addition, we contacted members of Cochrane Airways Group and experts in the field for further trials and unpublished materials.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-15 12:00:41 +0100" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="5">Study assessment </HEADING>
<P>Two members of the review team independently assessed the titles and abstracts of all identified citations. Decisions of the two reviewers were recorded (include or reject) and then compared, with any disagreements resolved by consensus. Two review authors evaluated the full text of all potentially eligible papers and made an independent decision whether to include or exclude each study according to the inclusion and exclusion criteria, with any disagreements again resolved by consensus. Studies that were excluded had their bibliographic details and reason for exclusion listed in the table &#8242;Characteristics of excluded studies&#8242;.</P>
<P>All trials included in the review were to be scored according to the adequacy of allocation concealment using the following grading system:</P>
<P>Grade A - Adequate concealment<BR/>Grade B - Unclear concealment<BR/>Grade C - Obviously not adequate concealment</P>
<P>Furthermore, we planned to assess each study using a 0 to 5 scale based upon the method described by Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) and summarised as follows:</P>
<P>Was the study described as randomised (1 = yes; 0 = no)?<BR/>Was the study described as being double blind (1= yes; 0 = no)?<BR/>Was there a description of withdrawals and dropouts (1= yes; 0 = no)?<BR/>Was the method of randomisation well described and appropriate (1 = yes; 0 = no)?<BR/>Was the method of double blinding well described and appropriate (1 = yes; 0 = no)?<BR/>Deduct 1 point if methods for randomisation or blinding were inappropriate.<BR/>
<BR/>Inter-rater reliability was to be measured using simple agreement, kappa and weighted kappa statistics.<BR/>In addition, each study was to be assessed for the reliability of a diagnosis of COPD using the criteria:</P>
<P>Was the age of the participants over 45 years?</P>
<P>Was the smoking history greater than 10 pack years?</P>
<P>Were participants with a previous physician diagnosis of asthma excluded?</P>
<P>Was t evidence of fixed airflow obstruction?</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Data Extraction </HEADING>
<P>One of the review authors was to extract data for the trials and send to the authors for verification. For those studies where verification could not be obtained, a second independent review author was to be used. Authors of studies were to be contacted to obtain missing information . All trials were to be combined using Review Manager 4.2.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Method of Analysis and Synthesis </HEADING>
<P>Forest plots would have been used to compare results across the trials.</P>
<P>For continuous variables, the pooled weighted mean difference (WMD),or standardised mean difference (SMD), with 95% confidence intervals (CI) were to be calculated using the Mantel-Haenszel fixed-effect method for dichotomous outcomes, the odds ratio (OR) with 95% confidence interval was to be calculated, and compared with the Risk Ratio (RR) and Risk Difference (RD). For time-to-event outcomes such as log hazard ratios, the fixed-effect generic inverse variance outcome were to be used to combine results. This method gives a weighted average of the effect estimates of separate studies (<LINK REF="REF-Deeks-2004" TYPE="REFERENCE">Deeks 2004</LINK>). Numbers Needed to Treat were to be calculated from the pooled Odds Ratio and its confidence interval, using the baseline risk in the control group.</P>
<P>An assessment of heterogeneity was to be carried out for pooled effects using a Breslow-Day test of heterogeneity with a P value &gt; 0.05 considered to indicate significant differences between studies. An approach known as the 'I square' was to be used to describe the percentage of total variation across studies that is due to heterogeneity rather than chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). A value &gt; 50% may be considered substantial heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bias</HEADING>
<P>We would attempts to obtain data from intention-to-treat and per-protocol populations. Sensitivity analyses were to be carried out for study quality and funnel plots were used to investigate publication bias.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-19 16:10:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-09-19 16:10:35 +0100" MODIFIED_BY="[Empty name]">
<P>The search identified a total of 741 potential titles, of which 18 were selected as potentially relevant and abstracts or full text articles retrieved. No additional studies were identified from references in published studies. Sixteen studies were excluded due to the following reasons: no oxygen control arm (n = 2), not a randomised controlled trial (n = 12), not performed in the pre-hospital environment (n = 2) and not an AECOPD (n = 2). There was complete agreement between two reviewers on the inclusion and exclusion of studies. Two ongoing studies were identified from insert where these were identified (<LINK REF="STD-Eiser-2004" TYPE="STUDY">Eiser 2004</LINK> and <LINK REF="STD-Elliott-2004" TYPE="STUDY">Elliott 2004</LINK>), but no data was available after contacting the authors. Description of these ongoing studies are in <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>. No new relevant studies were identified from searches between August 2005 to August 2008.</P>
<P>
<LINK REF="STD-Eiser-2004" TYPE="STUDY">Eiser 2004</LINK>
<BR/>
<B>Study Design</B>
<BR/>Randomised Controlled Trial</P>
<P>
<B>Participants</B>
<BR/>All patients presenting with symptoms of exacerbation of COPD conveyed to Lewisham Hospital by London Ambulance Service Emergency Medical Technicians meeting the following criteria: Age 45 years, have inhaler/nebuliser for regular home use, breathless on exertion of MC grade 2 or above when well, have a current or past smoking history</P>
<P>
<B>Interventions</B>
<BR/>Oxygen therapy to maintain oxygen saturation between 88% and 92% compared with standard oxygen therapy</P>
<P>
<B>Outcomes</B>
<BR/>Primary outcome: Arterial blood pH Secondary outcomes: need for intubation and mechanical ventilation, need for non invasive ventilation, hospital length of stay and survival</P>
<P>
<B>Notes</B>
<BR/>Randomisation has been based at the level of the ambulance crew, with half trained to administer controlled oxygen and the remainder using standard oxygen therapy. Contact : Dr. Noemi Eiser (Noemi.Eiser@uhl.nhs.uk)</P>
<P>
<LINK REF="STD-Elliott-2004" TYPE="STUDY">Elliott 2004</LINK>
<BR/>
<B>Study Design</B>
<BR/>Randomised controlled Trial<BR/>
<B>
<BR/>Participants</B>
<BR/>Patients who may have an exacerbation of COPD. Patients who can answer "yes" to the following questions 1) Age &gt; 45 2) having an inhaler or nebuliser for regular home use 3) breathlessness on exertion of MRC grade 2 or above when well 4) a current or past of smoking</P>
<P>
<B>Interventions</B>
<BR/>Oxygen targeted to maintain an oxygen saturation between 88 and 92% compared with standard therapy.</P>
<P>
<B>Outcomes</B>
<BR/>Primary outcome: pH &lt; 7.35. Secondary outcomes: need for intubation and mechanical ventilation, need for non invasive ventilation, hospital length of stay and survival.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Not applicable.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Not applicable. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-09-18 12:07:21 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The systematic review did not identify any completed randomised controlled trials comparing oxygen therapy at different concentrations or oxygen therapy versus placebo in the pre-hospital setting for the treatment of acute exacerbations of COPD. Two studies (<LINK REF="STD-Eiser-2004" TYPE="STUDY">Eiser 2004</LINK>; <LINK REF="STD-Elliott-2004" TYPE="STUDY">Elliott 2004</LINK>) were identified, but these are ongoing with no data available for analysis.</P>
<P>The traditional approach to treatment of patients with shortness of breath is 'high flow' oxygen adopted on the basis that the population as a whole are at greater risk from failure to correct oxygenation than from its excessive administration. The recent retrospective study by <LINK REF="STD-Dennston-2002" TYPE="STUDY">Dennston 2002</LINK>, found that the administration of an inspired oxygen concentration above 28% was associated with a higher in-hospital mortality (of 14%) than administration of a concentration of oxygen less that 28% (mortality of 2%). This raises questions about the optimal delivery of oxygen to people with COPD in the pre-hospital setting, but the non-randomised design means that the results could have been confounded by the severity of illness influencing the choice of oxygen concentration used. There is a need for a pre-hospital studies to investigate the optimum approach to the administration of oxygen for AECOPD to ensure we are not harming people with COPD by the administration of high flow oxygen. The ongoing studies identified in this review have, as with many pre-hospital studies, experienced difficulties with design, implementation and compliance of staff. However, this should not prevent us striving to obtain information from randomised controlled trials about the optimal oxygen treatment for exacerbations of COPD.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>No relevant trials have been published to date, thus there is no evidence to indicate that different oxygen therapies in the pre-hospital setting (prior to casualty/emergency department) alters outcomes in patients with acute exacerbations of COPD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is an urgent need for robust, well-designed randomised controlled trials to investigate the effect of different oxygen therapies in the pre-hospital setting to optimise the management of people with acute exacerbations of COPD. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Many thanks to the Cochrane Airways Group editorial base for support; Elizabeth Arnold for conducting the electronic searches, Toby Lasserson for support and Chris Cates for Editorial support . We would also like to thank Dr. Julia Walters for advice and support. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>There are no known conflicts of interest.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-09-18 12:07:27 +0100" MODIFIED_BY="Toby J Lasserson">
<P>MA: Protocol initiation &amp; development. Write-up<BR/>RWB: Protocol development. Revision of the review</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-19 16:13:05 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-09-19 16:12:37 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Costello-1997" NAME="Costello 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Costello R, Deegan P, Fitzpatrick M, McNicholas W. Reversible hypercapnia in chronic obstructive pulmonary disease: A distinct pattern of respiratory failure with a favorable prognosis. American Journal of Medicine 1997; 102(3):239-244.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costello R, Deegan P, Fitzpatrick M, McNicholas W</AU>
<TI>Reversible hypercapnia in chronic obstructive pulmonary disease: A distinct pattern of respiratory failure with a favorable prognosis</TI>
<SO>American Journal of Medicine</SO>
<YR>1997</YR>
<VL>102</VL>
<NO>3</NO>
<PG>239-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curtis-1994" NAME="Curtis 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Curtis J, Hudson L. Emergent assessment and management of acute respiratory failure in COPD. Clinics in Chest Medicine 1994; 15(3):481-500.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curtis J, Hudson L</AU>
<TI>Emergent assessment and management of acute respiratory failure in COPD</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>1994</YR>
<VL>15</VL>
<NO>3</NO>
<PG>481-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dennston-2002" NAME="Dennston 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Denniston A, O'Brien C, Stableforth D. The use of oxygen in acute exacerbations of chronic obstructive pulmonary disease: a prospective audit of pre-hospital and hospital emergency management.[see comment]. Clinical Medicine 2002; 2(5):449-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denniston A, O'Brien C, Stableforth D</AU>
<TI>The use of oxygen in acute exacerbations of chronic obstructive pulmonary disease: a prospective audit of pre-hospital and hospital emergency management</TI>
<SO>Clinical Medicine</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>5</NO>
<PG>449-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emerman-1989" NAME="Emerman 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Emerman C, Connors A, Lukens T, Effron D, May M. Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease. Annals of Emergency Medicine 1989; 18(5):523-527.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emerman C, Connors A, Lukens T, Effron D, May M</AU>
<TI>Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1989</YR>
<VL>18</VL>
<NO>5</NO>
<PG>523-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Esteban-1993" NAME="Esteban 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Esteban A, Cerda E, De La Cal M, Lorente J. Hemodynamic effects of oxygen therapy in patients with acute exacerbations of chronic obstructive pulmonary disease. Chest 1993; 104(2):471-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esteban A, Cerda E, De La Cal M, Lorente J</AU>
<TI>Hemodynamic effects of oxygen therapy in patients with acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>104</VL>
<NO>2</NO>
<PG>471-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomersall-2002" NAME="Gomersall 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Gomersall C, Joynt G, Freebairn R, Lai C, Oh T. Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical care medicine 2002;30(1):113-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomersall C, Joynt G, Freebairn R, Lai C, Oh T</AU>
<TI>Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study</TI>
<SO>Critical Care Medicine</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>1</NO>
<PG>113-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McNally-1993" NAME="McNally 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;McNally E, Fitzpatrick M, Bourke S, Costello R, McNicholas W. Reversible hypercapnia in acute exacerbations of chronic obstructive pulmonary disease (COPD). European Respiratory Journal 1993; 6(9):1353-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McNally E, Fitzpatrick M, Bourke S, Costello R, McNicholas W</AU>
<TI>Reversible hypercapnia in acute exacerbations of chronic obstructive pulmonary disease (COPD)</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>9</NO>
<PG>1353-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moloney-2001" NAME="Moloney 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Moloney E, Kiely J, McNicholas W. Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease. Lancet 2001; 357(9255):526-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moloney E, Kiely J, McNicholas W</AU>
<TI>Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9255</NO>
<PG>526-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-2001" NAME="Murphy 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Murphy R, Mackway-Jones K, Sammy I, Driscoll P, Gray A, O'Driscoll R, et al. Emergency oxygen therapy for the breathless patient. Guidelines prepared by North West Oxygen Group. Emergency Medicine Journal 2001; 18(6):421-423.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy R, Mackway-Jones K, Sammy I, Driscoll P, Gray A, O'Driscoll R, et al</AU>
<TI>Emergency oxygen therapy for the breathless patient. Guidelines prepared by North West Oxygen Group</TI>
<SO>Emergency Medicine Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>6</NO>
<PG>421-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-2001a" NAME="Murphy 2001a" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Murphy R, Driscoll P, O'Driscoll R. Emergency oxygen therapy for the COPD patient. Emergency Medicine Journal 2001; 18(5):333-339.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy R, Driscoll P, O'Driscoll R</AU>
<TI>Emergency oxygen therapy for the COPD patient</TI>
<SO>Emergency Medicine Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>5</NO>
<PG>333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Driscoll-2003" NAME="O'Driscoll 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;O'Driscoll R, Wolstenholme R, Pilling A, Bassett C, Singer M, Bellingan G, et al. The use of oxygen in acute exacerbations of chronic obstructive pulmonary disease: A prospective audit of pre-hospital and hospital emergency management [1] (multiple letters). Clinical Medicine 2003; 3(2):183-186.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Driscoll R, Wolstenholme R, Pilling A, Bassett C, Singer M, Bellingan G, et al</AU>
<TI>The use of oxygen in acute exacerbations of chronic obstructive pulmonary disease: A prospective audit of pre-hospital and hospital emergency management</TI>
<SO>Clinical Medicine</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>2</NO>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Reilly-2003" NAME="O'Reilly 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;O'Reilly J. Emergency management of acute exacerbation of chronic obstructive pulmonary disease. Cpd Journal Acute Medicine 2003; 2(1):3-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Reilly J</AU>
<TI>Emergency management of acute exacerbation of chronic obstructive pulmonary disease</TI>
<SO>Cpd Journal Acute Medicine</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>1</NO>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schumaker-2004" NAME="Schumaker 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Schumaker G, Epstein S. Managing acute respiratory failure during exacerbation of chronic obstructive pulmonary disease. [Review] [192 refs]. Respiratory Care 2004; 49(7):766-82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schumaker G, Epstein S</AU>
<TI>Managing acute respiratory failure during exacerbation of chronic obstructive pulmonary disease</TI>
<SO>Respiratory Care</SO>
<YR>2004</YR>
<VL>49</VL>
<NO>7</NO>
<PG>766-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Small-2000" NAME="Small 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Small G, Barsby P</AU>
<TI>How much is enough? Emergency oxygen therapy with COPD</TI>
<SO>Emergency Nurse</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>8</NO>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Elst-1982" NAME="Van der Elst 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Van der Elst A, Kreukniet J. Some aspects of the oxygen transport in patients with chronic obstructive lung diseases and respiratory insufficiency. Respiration 1982; 43(5):336-343.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van der Elst A, Kreukniet J</AU>
<TI>Some aspects of the oxygen transport in patients with chronic obstructive lung diseases and respiratory insufficiency</TI>
<SO>Respiration</SO>
<YR>1982</YR>
<VL>43</VL>
<NO>5</NO>
<PG>336-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Elst-1985" NAME="van der Elst 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;1. van der Elst A, van der Werf T. Some circulatory aspects of the oxygen transport in patients with emphysema. Respiration 1985; 48(4):310-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Elst A, van der Werf T</AU>
<TI>Some circulatory aspects of the oxygen transport in patients with emphysema</TI>
<SO>Respiration</SO>
<YR>1985</YR>
<VL>48</VL>
<NO>4</NO>
<PG>310-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2008-09-19 16:12:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Eiser-2004" MODIFIED="2008-09-19 16:12:30 +0100" MODIFIED_BY="[Empty name]" NAME="Eiser 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-19 16:12:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Eiser DN. Comparison of controlled oxygen with standard oxygen therapy for COPD patients during ambulance transfer to hospital. London Ambulance Service NHS Trust 2004;01/01/2005(Primary outcome measure: pH&amp;amp;lt;7.35. Secondary outcome measures: need for intubation and mechancial ventilation; need for non invasive ventillation; hospital length of stay and survival):Ongoing.&lt;/p&gt;" NOTES_MODIFIED="2008-09-19 16:12:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eiser DN</AU>
<TI>Comparison of controlled oxygen with standard oxygen therapy for COPD patients during ambulance transfer to hospital</TI>
<SO>London Ambulance Service NHS Trust</SO>
<YR>2004</YR>
<PG>Ongoing</PG>
<IDENTIFIERS MODIFIED="2008-09-19 16:12:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-19 16:12:30 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="N0352136077"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Elliott-2004" MODIFIED="2008-09-19 16:12:37 +0100" MODIFIED_BY="[Empty name]" NAME="Elliott 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-19 16:12:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Elliott DMWE. A prospective randomised controlled trial of oxygen targeted to maintain an oxygen saturation between 88 and 92% compared with standard therapy for patients with COPD during ambulance transfer to hospital. Leeds Teaching Hospitals NHS Trust 2004;1/9/2005(Patients will be randomised either to usual oxygen therapy or to having the oxygen flow rate adjusted to achieve a saturation between 88 and 92%. During the nebulisation of brochodilators patients randomised to the targetted delivery group will have the):Ongoing.&lt;/p&gt;" NOTES_MODIFIED="2008-09-19 16:12:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Elliott DM</AU>
<TI>A prospective randomised controlled trial of oxygen targeted to maintain an oxygen saturation between 88 and 92% compared with standard therapy for patients with COPD during ambulance transfer to hospital</TI>
<SO>Leeds Teaching Hospitals NHS Trust</SO>
<YR>2004</YR>
<PG>Ongoing</PG>
<IDENTIFIERS MODIFIED="2008-09-19 16:12:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-19 16:12:37 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="N0436146646"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-19 16:13:05 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-19 16:13:05 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Deeks-2004" MODIFIED="2008-09-19 16:13:05 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2004" TYPE="BOOK_SECTION">
<AU>Deeks J, Higgins J, Altman D</AU>
<TI>Analysing and presenting results</TI>
<SO>Cochrane Reviewers' Handbook Version 4.2.2. Section 8 [available at: http://www.cochrane.org/resources/handbook/hbook.htm]</SO>
<YR>2004</YR>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denniston-2002" MODIFIED="2008-08-15 12:00:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Denniston 2002" TYPE="JOURNAL_ARTICLE">
<AU>Denniston A, O'Brien C, Stableforth D</AU>
<TI>The use of oxygen in acute exacerbations of chronic obstructive pulmonary disease: a prospective audit of pre-hospital and hospital emergency management</TI>
<SO>Clinical Medicine</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>5</NO>
<PG>449-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Groenewegen-2003" MODIFIED="2008-08-15 12:00:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Groenewegen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Groenewegen KH, Schols AM, Wouters EF</AU>
<TI>Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>124</VL>
<PG>459-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulsvik-2001" MODIFIED="2008-08-15 12:00:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Gulsvik 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gulsvik, A</AU>
<TI>The global burden and impact of chronic obstructive pulmonary disease worldwide</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-08-15 12:00:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JD, Altman G</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-09-18 12:07:53 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds J, Gavaghan D, et al</AU>
<TI>Assessing the quality of reports of randomised control trials: is blinding really necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1997" MODIFIED="2008-08-15 12:00:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Murray 1997" TYPE="JOURNAL_ARTICLE">
<AU>Murray CJ, Lopex AD</AU>
<TI>Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9064</NO>
<PG>1498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plant-2001" MODIFIED="2008-08-15 12:00:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Plant 2001" TYPE="JOURNAL_ARTICLE">
<AU>Plant PK, Owen JL, Elliott MW</AU>
<TI>Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome</TI>
<SO>Thorax</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>708-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warren-1980" MODIFIED="2008-08-15 12:00:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Warren 1980" TYPE="JOURNAL_ARTICLE">
<AU>Warren PM, Flenley DC, Millar JS, Avery A</AU>
<TI>Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-68 and 1970-76</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>476-0</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-09-18 12:07:38 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Costello-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Clinical Audit of outcomes, Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Curtis-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dennston-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Emerman-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not compared with oxygen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Esteban-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a pre-hospital study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gomersall-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a pre-hospital study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McNally-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT of oxygen levels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moloney-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murphy-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murphy-2001a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Driscoll-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Reilly-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schumaker-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Small-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-der-Elst-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not AECOPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Elst-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not AECOPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AECOPD: Acute exacerbations of chronic obstructive pulmonary disease <BR/>RCT: Randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-09-18 12:07:38 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Eiser-2004">
<CHAR_STUDY_NAME>
<P>Comparison of controlled oxygen with standard oxygen therapy for COPD patients during ambulance transfer to hospital</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>All patients presenting with symptoms of exacerbation of COPD conveyed to Lewisham Hospital by London Ambulance Service Emergency Medical Technicians meeting the following criteria: Age&amp;gt; 45 years, have inhaler/nebuliser for regular home use, breathless on exertion of MC grade 2 or above when well, have a current or past smoking history</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oxygen therapy to maintain oxygen saturation between 88% and 92%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Blood pH Secondary: need for intubation and mechanical ventilation, need for non invasive ventilation, hospital length of stay and survival</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Dr. Noemi Eiser <BR/>University Hospital Lewisham NHS trust, Lewisham High Street, London, SE13 6LH, United Kingdom<BR/>Phone: +44 208 333 3030<BR/>Email: Noemi.Eiser@uhl.nhs.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Consenting patients will be randomised to receive either standard oxygen therapy or an adjusted oxygen flow rate to achieve a saturation between 88% and 92%. Half of ambulance crews will be trained to administer controlled oxygen and randomisation will be based on which ambulance crew is called to the patient</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-09-18 12:07:38 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Elliott-2004">
<CHAR_STUDY_NAME>
<P>The prospective randomised controlled trial of oxygen targeted to maintain an oxygen saturation between 88 and 92% compared with standard therapy for patients with COPD during ambulance transfer to hospital</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients who may have an exacerbation of COPD. Patients who can answer "yes" to the following questions 1) Age &gt; 45 2) having an inhaler or nebuliser for regular home use 3) breathlessness on exertion of MRC grade 2 or above when well 4) a current or past of smoking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oxygen therapy to maintain oxygen saturation between 88% and 92%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-18 12:07:38 +0100" MODIFIED_BY="Toby J Lasserson">
<P>To establish whether oxygen delivery given to achieve a specific oxygen saturation and nebulised drugs given via a compressor (standard practice on Respiratory wards at St James's) results in fewer patients presenting to hospital acidotic or needing ventilation</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Dr. Mark Elliott<BR/>Respiratory Medicine, Gledhow Wing, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, England<BR/>email: mwelliott@doctors.org.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Randomised controlled trial Random allocation to [A] usual oxygen therapy [B] the oxygen flow rate adjusted to achieve a saturation between 88 and 92%<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>COPD: Chronic obstructive pulmonary disease <BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-19 16:09:07 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-19 16:08:56 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-09-19 16:08:56 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-09-19 16:08:52 +0100" MODIFIED_BY="[Empty name]">Database search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-19 16:08:56 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search</P>
</TH>
</TR>
<TR>
<TD>
<P>MEDLINE<BR/>(Combined with RCT filter)</P>
</TD>
<TD>
<P>1. exp PULMONARY DISEASE, CHRONIC OBSTRUCTIVE/<BR/>2. bronchit$.mp.<BR/>3. emphysema$.mp.<BR/>4. (copd or coad or cobd).mp.<BR/>5. (lung$ or respirat$ or pulmonar$ or airway$ or airflow$).mp.<BR/>6. (chronic$ adj3 obstructi$).mp.<BR/>7. 5 and 6<BR/>8. 1 or 2 or 3 or 4 or 7<BR/>9. exp Emergency Medical Services/<BR/>10. emergenc$.mp.<BR/>11. (emergicent$ or emergi-cent$).mp.<BR/>12. prehospital$.mp.<BR/>13. pre-hospital.mp.<BR/>14. hospital$.mp.<BR/>15. ambulance$.mp.<BR/>16. (patient$ adj3 transport$).mp.<BR/>17. exp Emergency Treatment/<BR/>18. first-aid$.mp.<BR/>19. first aid$.mp.<BR/>20. or/9-19<BR/>21. exp oxygen inhalation therapy/<BR/>22. OXYGEN/ad, tu [Administration &amp; Dosage, Therapeutic Use]<BR/>23. oxygen$.mp.<BR/>24. (inhal$ adj3 therap$).mp<BR/>25. (respirat$ adj3 therap$).mp.<BR/>26. nasal cannula.mp.<BR/>27. nasal prong$.mp.<BR/>28. NRM.mp.<BR/>29. Hudson$.mp.<BR/>30. Venture$.mp.<BR/>31. mask$.mp.<BR/>32. or/21-31<BR/>33. 32 and 20 and 8<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE<BR/>(Combined with RCT filter)</P>
</TD>
<TD>
<P>1. exp Chronic Obstructive Lung Disease/<BR/>2. bronchiti$.mp.<BR/>3. emphysema$.mp.<BR/>4. (copd or coad or cobd).mp.<BR/>5. (lung$ or respirat$ or pulmonar$ or airway$ or airflow$).mp.<BR/>6. (chronic$ adj3 obstructi$).mp.<BR/>7. 5 and 6<BR/>8. 1 or 2 or 3 or 4 or 7<BR/>9. exp Emergency Health Service/<BR/>10. patient transport/<BR/>11. exp ambulance/<BR/>12. emergenc$.mp.<BR/>13. emergicent$.mp.<BR/>14. emergi-cent$.mp.<BR/>15. prehospital$.mp.<BR/>16. pre-hospital$.mp.<BR/>17. hospital$.mp.<BR/>18. ambulance$.mp.<BR/>19. (patient$ adj3 transport$).mp.<BR/>20. emergency treatment/ or first aid/<BR/>21. first-aid$.mp.<BR/>22. first aid$.mp.<BR/>23. or/9-22<BR/>24. oxygen therapy/<BR/>25. OXYGEN/ad, ih [Drug Administration, Inhalational Drug Administration]<BR/>26. oxygen$.mp.<BR/>27. (inhal$ adj3 therap$).mp.<BR/>28. (respirat$ adj3 therap$).mp.<BR/>29. nasal cannula.mp.<BR/>30. nasal prong$.mp.<BR/>31. NRM.mp.<BR/>32. Hudson$.mp.<BR/>33. Venture$.mp.<BR/>34. mask$.mp.<BR/>35. or/24-34<BR/>36. 35 and 23 and 8<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>CINAHL<BR/>(Combined with RCT filter)</P>
</TD>
<TD>
<P>1. exp Lung Diseases, Obstructive/<BR/>2. bronchit$.mp.<BR/>3. emphysema$.mp.<BR/>4. (copd or coad or cobd).mp.<BR/>5. (lung$ or respirat$ or pulmonar$ or airway$ or airflow$).mp.<BR/>6. (chronic$ adj3 obstructi$).mp.<BR/>7. 5 and 6<BR/>8. 1 or 2 or 3 or 4 or 7<BR/>9. exp Emergency Medical Services/<BR/>10. emergenc$.mp.<BR/>11. (emergicent$ or emergi-cent$).mp.<BR/>12. prehospital$.mp.<BR/>13. pre-hospital.mp.<BR/>14. hospital$.mp.<BR/>15. ambulance$.mp.<BR/>16. (patient$ adj3 transport$).mp.<BR/>17. exp Emergency Care/<BR/>18. First Aid/<BR/>19. first aid$.mp.<BR/>20. first-aid$.mp.<BR/>21. or/9-20<BR/>22. Oxygen Therapy/<BR/>23. Oxygen/ad, tu [Administration and Dosage, Therapeutic use]<BR/>24. oxygen$.mp.<BR/>25. (inhal$ adj3 therap$).mp.<BR/>26. (respirat$ adj3 therap$).mp.<BR/>27. nasal cannula.mp.<BR/>28. nasal prong$.mp.<BR/>29. NRM.mp.<BR/>30. Hudson$.mp.<BR/>31. Venture$.mp.<BR/>32. mask$.mp.<BR/>33. or/22-32<BR/>34. 33 and 21 and 8<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>